Drug intelligence / Profile preview

cyclophosphamide + etoposide + vincristine + prednisone

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

CEOP is a chemotherapy regimen consisting of cyclophosphamide, etoposide, vincristine, and prednisone. It is primarily used in the treatment of peripheral T-cell lymphomas (PTCL) and other aggressive lymphomas. This regimen is a modification of the standard CHOP regimen, where etoposide replaces doxorubicin. The typical dosing schedule includes cyclophosphamide 750 mg/m² IV on day 1, etoposide 100 mg/m² IV on days 1-3, vincristine 2 mg IV on day 1, and prednisone 100 mg/day for 5 days.

Targets

GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)DNAMicrotubule

Beyond the preview

Go deeper on cyclophosphamide + etoposide + vincristine + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + etoposide + vincristine + prednisone.

Explore the full profile